22122 Reaping the Rewards of Innovative Care in CLL: From Targeted Standards to Cellular Therapy

​​​​​​​Gain the skills you need to adapt your current management protocols to reflect the new treatment reality in chronic lymphocytic leukemia (CLL), utilize novel combinatorial and sequential strategies, and map out the role of emerging cell-based therapies! In this activity, expert hematologist-oncologists provide expert guidance on the transformed nature of modern CLL management, the practice-changing evidence that validated targeted therapy platforms, and the science that is redefining the roles of hematopoietic stem cell transplantation and cellular therapy, including in challenging pretreated CLL settings.

his activity can be accessed using the following URL: www.peerview.com/GUR

This activity is supported through educational grants from Bristol Meyers Squibb.

 

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other healthcare professionals involved in the management of CLL.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Cite current guidelines and evidence on the treatment roles of hematopoietic stem cell transplantation; BTK, PI3K, and BCL-2 inhibitors; monoclonal antibodies; and CAR-T cell therapy in the CLL setting
  • Discuss evidence surrounding the efficacy and safety of novel therapeutics across the spectrum of CLL, including in higher-risk disease settings or in patients relapsing after multiple prior treatments
  • Recommend regimens with novel components for patients presenting with treatment-naïve, high-risk, or relapsed/refractory CLL
Additional information

Contact

Name: 
Mallory Ahern
Phone Number: 
+1 (914) 737-6528
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
05/24/2022
Course expires: 
05/25/2023
Cost:
$0.00
Rating: 
0

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chairs & Presenters
John N. Allan, MD
Assistant Professor of Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, New York

John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; ADC Therapeutics SA; AstraZeneca; BeiGene; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Pharmacyclics LLC; and TG Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; AstraZeneca; BeiGene; Celgene Corporation; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Speakers Bureau participant with AbbVie Inc.; AstraZeneca; BeiGene; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.

Alexey V. Danilov, MD, PhD
Professor and Co-Director
Toni Stephenson Lymphoma Center
City of Hope National Medical Center
Duarte, California

Alexey V. Danilov, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bayer Oncology; BeiGene; Genentech, Inc.; MEI Pharma, Inc.; Nurix Therapeutics, Inc.; Oncovalent Therapeutics; Pharmacyclics LLC; and TG Therapeutics, Inc.
Grant/Research Support from AstraZeneca; Bayer Oncology; Bristol-Myers Squibb; Genentech, Inc.; MEI Pharma, Inc.; Secura Bio, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and TG Therapeutics, Inc.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is co-provided with our educational partner, PVI, PeerView Institute for Medical Education.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.